Timothy P. Cripe

8.2k total citations
174 papers, 6.2k citations indexed

About

Timothy P. Cripe is a scholar working on Genetics, Oncology and Molecular Biology. According to data from OpenAlex, Timothy P. Cripe has authored 174 papers receiving a total of 6.2k indexed citations (citations by other indexed papers that have themselves been cited), including 88 papers in Genetics, 72 papers in Oncology and 40 papers in Molecular Biology. Recurrent topics in Timothy P. Cripe's work include Virus-based gene therapy research (83 papers), CAR-T cell therapy research (53 papers) and Neuroblastoma Research and Treatments (33 papers). Timothy P. Cripe is often cited by papers focused on Virus-based gene therapy research (83 papers), CAR-T cell therapy research (53 papers) and Neuroblastoma Research and Treatments (33 papers). Timothy P. Cripe collaborates with scholars based in United States, Netherlands and Italy. Timothy P. Cripe's co-authors include Mark A. Currier, L P Turek, Yonatan Y. Mahller, Nancy Ratner, Thomas H. Haugen, Mary Frances Wedekind, Chun‐Yu Chen, Balveen Kaur, Margaret H. Collins and Teresa L. Andreone and has published in prestigious journals such as Nature, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

In The Last Decade

Timothy P. Cripe

167 papers receiving 6.1k citations

Peers

Countries citing papers authored by Timothy P. Cripe

Since Specialization

Citations

This map shows the geographic impact of Timothy P. Cripe's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Timothy P. Cripe with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Timothy P. Cripe more than expected).

Fields of papers citing papers by Timothy P. Cripe

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Timothy P. Cripe. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Timothy P. Cripe. The network helps show where Timothy P. Cripe may publish in the future.

Co-authorship network of co-authors of Timothy P. Cripe

This figure shows the co-authorship network connecting the top 25 collaborators of Timothy P. Cripe. A scholar is included among the top collaborators of Timothy P. Cripe based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Timothy P. Cripe. Timothy P. Cripe is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Trabectedin Enhances the Antitumor Effects of IL-12 in Triple-Negative Breast Cancer 2025 ·Cancer Immunology Research ·Emily Schwarz, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Lianbo Yu, Gregory K. Behbehani, Timothy P. Cripe, William E. Carson	2
2	Local Control and Toxicity Outcomes After Stereotactic Body Radiation Therapy for Metastatic Osteosarcoma in Pediatric Patients 2025 ·Pediatric Blood & Cancer ·(unknown), Rituraj Upadhyay, Brett Klamer, Raj Singh, David J. Konieczkowski, Timothy P. Cripe, Nicholas D. Yeager, Ryan D. Roberts, Jennifer H. Aldrink, Bhuvana A. Setty, Thomas J. Scharschmidt, Joshua D. Palmer, Sujith Baliga	0
3	Intratumoral/Peritumoral Herpes Simplex Virus-1 Mutant HSV1716 in Pediatric Patients with Refractory or Recurrent High-Grade Gliomas: A Report of the Pediatric Brain Tumor Consortium 2024 ·SHILAP Revista de lepidopterología ·Aaron Mochizuki, Trent R. Hummel, Timothy P. Cripe, Maryam Fouladi, Ian F. Pollack, Duane A. Mitchell, Tina Young Poussaint, (unknown), (unknown), (unknown), Charles B. Stevenson	0
4	Combinatorial immunotherapy with anti-ROR1 CAR NK cells and an IL-21 secreting oncolytic virus against neuroblastoma 2024 ·SHILAP Revista de lepidopterología ·Yaya Chu, (unknown), Uksha Saini, (unknown), (unknown), (unknown), (unknown), M. Fevzi Özkaynak, Wen Luo, Timothy P. Cripe, Dean A. Lee, Kevin A. Cassady, Mitchell S. Cairo	5
5	Combinatorial immunotherapy of anti-MCAM CAR-modified expanded natural killer cells and NKTR-255 against neuroblastoma 2024 ·PubMed ·(unknown), (unknown), Hoang Hai, Yaya Chu, (unknown), Yanling Liao, Janet Ayello, Jeremy Rosenblum, Xiaokui Mo, (unknown), Willem W. Overwijk, Timothy P. Cripe, Dean A. Lee, Mitchell S. Cairo	0
6	Opportunities and challenges of combining adoptive cellular therapy with oncolytic virotherapy 2023 ·Molecular Therapy — Oncolytics ·(unknown), Chun‐Yu Chen, Mark A. Currier, Kevin A. Cassady, Dean A. Lee, Timothy P. Cripe	12
7	The quest for effective immunotherapies against malignant peripheral nerve sheath tumors: Is there hope? 2023 ·Molecular Therapy — Oncolytics ·(unknown), Brian Hutzen, Timothy P. Cripe	7
8	Drug Targeting the Actin Cytoskeleton Potentiates the Cytotoxicity of Low Dose Vincristine by Abrogating Actin-Mediated Repair of Spindle Defects 2020 ·Molecular Cancer Research ·Yao Wang, Jeffrey H. Stear, (unknown), Xing Xu, Nicole S. Bryce, Michael Carnell, Irina B. Alieva, Vera B. Dugina, Timothy P. Cripe, Justine Stehn, Edna C. Hardeman, Peter W. Gunning	13
9	Identification of Cancer-Targeted Tropomyosin Inhibitors and Their Synergy with Microtubule Drugs 2017 ·Molecular Cancer Therapeutics ·Mark A. Currier, Justine Stehn, (unknown), Duo Chen, Jeff Hook, (unknown), Andrew Heaton, David Brown, (unknown), David Eaves, (unknown), Herbert Treutlein, Jun Zeng, Irina B. Alieva, Vera B. Dugina, Edna C. Hardeman, Peter W. Gunning, Timothy P. Cripe	36
10	Intratumoral Injection of HSV1716, an Oncolytic Herpes Virus, Is Safe and Shows Evidence of Immune Response and Viral Replication in Young Cancer Patients 2017 ·Clinical Cancer Research ·Keri A. Streby, James I. Geller, Mark A. Currier, Patrick Warren, John M. Racadio, Alexander J. Towbin, (unknown), (unknown), (unknown), (unknown), Lori R. Backus, (unknown), (unknown), Kathleen Simpson, (unknown), Joe Conner, Timothy P. Cripe	109
11	Shorter-Duration Therapy Using Vincristine, Dactinomycin, and Lower-Dose Cyclophosphamide With or Without Radiotherapy for Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma: A Report From the Soft Tissue Sarcoma Committee of the Children's Oncology Group 2014 ·Journal of Clinical Oncology ·David Walterhouse, Alberto S. Pappo, Jane L. Meza, John C. Breneman, Andrea Hayes‐Jordan, David M. Parham, Timothy P. Cripe, James R. Anderson, William H. Meyer, Douglas S. Hawkins	100
12	Bortezomib-Induced Unfolded Protein Response Increases Oncolytic HSV-1 Replication Resulting in Synergistic Antitumor Effects 2014 ·Clinical Cancer Research ·Ji Young Yoo, Brian Hurwitz, Chelsea Bolyard, (unknown), Jianying Zhang, Karuppaiyah Selvendiran, Kellie S. Rath, Shun He, Zachary S. Bailey, David Eaves, Timothy P. Cripe, Deborah S. Parris, Michael A. Caligiuri, Jianhua Yu, Matthew Old, Balveen Kaur	64
13	Doxorubicin Synergizes with 34.5ENVE to Enhance Antitumor Efficacy against Metastatic Ovarian Cancer 2014 ·Clinical Cancer Research ·Chelsea Bolyard, Ji Young Yoo, Pin-Yi Wang, Uksha Saini, Kellie S. Rath, Timothy P. Cripe, Jianying Zhang, Karuppaiyah Selvendiran, Balveen Kaur	26
14	Ras-Driven Transcriptome Analysis Identifies Aurora Kinase A as a Potential Malignant Peripheral Nerve Sheath Tumor Therapeutic Target 2012 ·Clinical Cancer Research ·Ami V. Patel, David Eaves, Walter J. Jessen, Tilat A. Rizvi, Jeffrey Ecsedy, Mark G. Qian, Bruce J. Aronow, John P. Perentesis, Eduard Serra, Timothy P. Cripe, Shyra J. Miller, Nancy Ratner	47
15	In Vivo Regulation of TGF-β by R-Ras2 Revealed through Loss of the RasGAP Protein NF1 2012 ·Cancer Research ·Deanna M. Patmore, Sara Welch, Patricia C. Fulkerson, Jianqiang Wu, Kwangmin Choi, David Eaves, Jennifer J. Kordich, Margaret H. Collins, Timothy P. Cripe, Nancy Ratner	18
16	Chondroitinase ABC I–Mediated Enhancement of Oncolytic Virus Spread and Antitumor Efficacy 2010 ·Clinical Cancer Research ·Nina Dmitrieva, Lianbo Yu, Mariano S. Viapiano, Timothy P. Cripe, E. Antonio Chiocca, Joseph C. Glorioso, Balveen Kaur	70
17	Cancer-Selective Targeting and Cytotoxicity by Liposomal-Coupled Lysosomal Saposin C Protein 2009 ·Clinical Cancer Research ·Xiaoyang Qi, Zhengtao Chu, Yonatan Y. Mahller, Keith Stringer, David P. Witte, Timothy P. Cripe	52
18	Overexpression of the Cellular DEK Protein Promotes Epithelial Transformation In vitro and In vivo 2009 ·Cancer Research ·Trisha M. Wise‐Draper, (unknown), (unknown), (unknown), Kathryn A. Wikenheiser‐Brokamp, Mark A. Currier, Timothy P. Cripe, Gerard C. Grosveld, Susanne I. Wells	75
19	Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors 2008 ·Molecular Cancer Therapeutics ·Gunnar Johansson, Yonatan Y. Mahller, Margaret H. Collins, Mi‐Ok Kim, Takahiro Nobukuni, John P. Perentesis, Timothy P. Cripe, Heidi A. Lane, Sara C. Kozma, George Thomas, Nancy Ratner	104
20	Tissue Inhibitor of Metalloproteinase-3 via Oncolytic Herpesvirus Inhibits Tumor Growth and Vascular Progenitors 2008 ·Cancer Research ·Yonatan Y. Mahller, Sachin S. Vaikunth, (unknown), William H. Baird, Yoshinaga Saeki, José A. Cancelas, Timothy M. Crombleholme, Timothy P. Cripe	74

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact